New psoriasis pill shows promise in early trial
NCT ID NCT05725057
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 22 times
Summary
This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to check safety and side effects, with some early looks at whether the drug improves skin symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accellacare North London
Northwood, United Kingdom
-
Accellacare Northamptonshire
Corby, United Kingdom
-
Accellacare South London
Orpington, United Kingdom
-
Accellacare Warwickshire
Coventry, United Kingdom
-
Accellacare Yorkshire
Shipley, United Kingdom
-
MEU
Manchester, United Kingdom
Conditions
Explore the condition pages connected to this study.